Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849469 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT03849469 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 78 participants.
The verdict
NCT03849469, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
Interventions
- BIOLOGICAL XmAb®22841
- BIOLOGICAL Pembrolizumab (Keytruda®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2023-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03849469
The ClinicalTrials.gov registry entry for NCT03849469 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb®22841 is the first listed.
NCT03849469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03849469 about?
NCT03849469 is a clinical study titled "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors". This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor a...
What is the current status of trial NCT03849469?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2019-05-29. Estimated completion is 2023-02-16.
What interventions are being tested in trial NCT03849469?
The interventions under investigation include: XmAb®22841 (BIOLOGICAL), Pembrolizumab (Keytruda®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03849469?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.